Page last updated: 2024-11-07

15-acetoxyscirpen-3,4-diol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

15-acetoxyscirpen-3,4-diol: hydrolysis product of anguidine [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID429922
CHEBI ID175144
MeSH IDM0067335

Synonyms (29)

Synonym
CHEBI:175144
(10,11-dihydroxy-1,5-dimethylspiro[8-oxatricyclo[7.2.1.02,7]dodec-5-ene-12,2'-oxirane]-2-yl)methyl acetate
anguidine,4-diol-bl5732)
nsc-267030
desacetylanguidine
trichothec-9-ene-3,15-triol, 12,13-epoxy-, 15-acetate, (3.alpha.,4.beta.)-
trichothec-9-ene-3.alpha.,15-triol, 12,13-epoxy-, 15-acetate
nsc267030
2623-22-5
15-acetoxyscirpen-3,4-diol
15-acetylscirpenetriol
deacetylanguidin
15-o-acetylscirpenetriol
monoacetoxyscirpenol
nsc 267030
15-mono-o-acetylscirpenol
15-acetoxyscirpenol
4-deacetylanguidin
IRXDUBNENLKYTC-UHFFFAOYSA-N
scirp-9-ene-3.alpha.,4.beta.,15-triol, 12,13-epoxy-, 15-acetate
(3.alpha.)-12,13-epoxytrichothec-9-ene-3,4,15-triol 15-acetate
trichothec-9-ene-3,4,15-triol, 12,13-epoxy-, 15-acetate, (3.alpha.,4.beta.)-
trichothec-9-ene-3.alpha.,4.beta.,15-triol, 12,13-epoxy-, 15-acetate
15-mas
15-acetoxy-3alpha,4beta-dihydroxy-12,13-epoxytrichothec-9-ene
trichothec-9-ene-3alpha,4alpha,4beta)-
anguidine, desacetyl(15-acetoxyscirpene-3,4-diol-bl5732)
15-monoacetoxyscirpenol
F85597
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
trichotheceneAny one of a large family of chemically related mycotoxins with a structure based on a sesquiterpene skeleton. The most important structural features causing the biological activities of trichothecenes are a 12,13-epoxy ring, the presence of hydroxy or acetyl groups at appropriate positions on the trichothecene nucleus and the structure and position of the side-chain.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (20.00)18.7374
1990's2 (40.00)18.2507
2000's0 (0.00)29.6817
2010's2 (40.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]